Leqvio (Inclisiran)
Provider Summary
Primary Uses
Adjunct to diet and statin therapy for LDL-C reduction in selected adults per payer/clinical criteria.
Mechanism of action
Small interfering RNA (siRNA) that reduces hepatic production of PCSK9, increasing LDL receptor recycling and lowering LDL cholesterol.
Pre-treatment / baseline requirements
Baseline lipid panel; assess adherence/intolerance to maximally tolerated statin therapy; consider baseline liver tests per clinician preference; pregnancy status when applicable.
Common side effects
Injection-site reactions (pain, erythema), arthralgia.
Serious adverse effects / key risks
Hypersensitivity reactions (rare); class/label-specific risks per PI.
Clinical notes
Often used within a structured lipid management plan with follow-up lipid panels.
Referral requirements
Standard infusion referral form + drug-specific checklist
Typical dosing schedule
Single SQ injection at Day 0, again at 3 months, then every 6 months (twice yearly).
Patient & Caregiver Education
What it treats
Adjunct to diet and statin therapy for LDL-C reduction in selected adults
How it works
Lowers PCSK9 made by the liver, helping the body remove more LDL (“bad”) cholesterol
Before treatment
tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Injection-site reactions, arthralgia
Get urgent help for
Injection-site reactions, arthralgia
On treatment day
plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.